Spyre Therapeutics (SYRE) Net Income towards Common Stockholders (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Net Income towards Common Stockholders data on file, last reported at -$69.0 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 54.12% year-over-year to -$69.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$179.4 million (up 14.12% YoY) and the FY2025 annual result came in at -$155.2 million, up 25.39% from the prior year.
• Net Income towards Common Stockholders eased to -$69.0 million in Q1 2026, from -$62.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$11.2 million in Q3 2025 to a low of -$217.1 million in Q2 2023.
• A 5-year average of -$50.3 million and a median of -$40.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders sank 872.45% — and 2025, when it surged 83.8%.
• Tracing SYRE's Net Income towards Common Stockholders over 5 years: stood at -$18.8 million in 2022, then slumped by 235.67% to -$63.2 million in 2023, then advanced by 10.9% to -$56.3 million in 2024, then decreased by 11.07% to -$62.5 million in 2025, then dropped by 10.36% to -$69.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$69.0 million (Q1 2026), -$62.5 million (Q4 2025), and -$11.2 million (Q3 2025), per Business Quant data.